6XC Stock Overview A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Soleno Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Soleno Therapeutics Historical stock prices Current Share Price US$42.76 52 Week High US$54.60 52 Week Low US$32.90 Beta -1.53 1 Month Change -10.24% 3 Month Change -3.43% 1 Year Change 25.40% 3 Year Change 654.14% 5 Year Change 17.80% Change since IPO 71.73%
Recent News & Updates Soleno Therapeutics, Inc. announced that it expects to receive $200 million in funding Dec 18
Soleno Therapeutics, Inc. Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome Nov 26
Forecast to breakeven in 2026 Nov 08
Soleno Therapeutics Announces Regulatory Update on DCCR (Diazoxide Choline) Extended-Release Tablets to Treat Prader-Willi Syndrome Oct 09
President recently sold €966k worth of stock Oct 06
President recently sold €4.9m worth of stock Sep 02 See more updates Soleno Therapeutics, Inc. announced that it expects to receive $200 million in funding Dec 18
Soleno Therapeutics, Inc. Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome Nov 26
Forecast to breakeven in 2026 Nov 08
Soleno Therapeutics Announces Regulatory Update on DCCR (Diazoxide Choline) Extended-Release Tablets to Treat Prader-Willi Syndrome Oct 09
President recently sold €966k worth of stock Oct 06
President recently sold €4.9m worth of stock Sep 02
Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome Aug 28
Soleno Therapeutics, Inc. Announces Board Changes Aug 15
No longer forecast to breakeven Aug 09
President recently sold €5.3m worth of stock Aug 08 Soleno Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million. Jul 20
President recently sold €746k worth of stock Jul 07
Soleno Therapeutics, Inc Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome Jun 28
New minor risk - Share price stability Jun 06
Insufficient new directors May 27
Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024 May 23 Soleno Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $138 million.
Soleno Therapeutics, Inc. Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS) Apr 30
Soleno Therapeutics, Inc., Annual General Meeting, Jun 06, 2024 Apr 23
President recently sold €731k worth of stock Apr 05
Soleno Therapeutics Strengthens Leadership Team with Key Appointments Jan 24
Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open Label Study of DCCR in Prader-Willi Syndrome Nov 07 Soleno Therapeutics, Inc. announced that it has received $59.98825 million in funding Oct 05
New major risk - Shareholder dilution Sep 30 Soleno Therapeutics, Inc. announced that it expects to receive $30 million in funding Sep 28
Soleno Therapeutics, Inc. Announces Positive Statistically Significant Top-Line Results from Randomized Withdrawal Period of Study C602 of Dccr for Prader-Willi Syndrome Sep 27
Insufficient new directors Aug 21
Soleno Therapeutics Appoints Matthew Pauls to Board of Directors Aug 17
New major risk - Financial position Aug 11
No longer forecast to breakeven Jul 13
No longer forecast to breakeven May 11 Soleno Therapeutics, Inc. announced that it has received $10.000044 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P. May 10
Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome May 05
Soleno Therapeutics, Inc. Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome Jan 28
Forecast to breakeven in 2025 Dec 31 Soleno Therapeutics, Inc. announced that it expects to receive $59.89 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P. Dec 20
Insufficient new directors Nov 16
Soleno Therapeutics, Inc. Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome Oct 04
Insufficient new directors Aug 01
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome Jul 21
Insufficient new directors Jul 02
Soleno Therapeutics, Inc., Annual General Meeting, Jun 01, 2022 Apr 22
Soleno Therapeutics Provides Regulatory Update on Dccr for the Treatment of Prader-Willi Syndrome Jan 25
Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of Pws Following One Year Treatment with Dccr Sep 10 Soleno Therapeutics, Inc.(NasdaqCM:SLNO) dropped from Russell 3000E Growth Index
Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1A Jun 03
Soleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome May 05
New 90-day low: €1.16 Mar 10
Soleno Therapeutics, Inc. Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome Mar 10
Soleno Therapeutics Announces Collaboration with Vanderbilt University to Discover and Develop Next Generation K(ATP) Channel Activators for the Treatment of Rare Diseases Feb 24
New 90-day high: €2.24 Feb 07
Soleno Therapeutics, Inc. Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome Feb 06
New 90-day high: €1.74 Jan 09
Soleno Therapeutics Provides Regulatory Update on Dccr for the Treatment of Prader-Willi Syndrome Dec 13
Soleno Therapeutics Announces Presentation of Body Composition Results from DESTINY PWS, a Phase III Trial of DCCR in Prader-Willi Syndrome Nov 05
New 90-day low: €1.36 Oct 30
Soleno Therapeutics, Inc. Announces the Body Composition Data from the Company’s Phase III trial, DESTINY PWS (C601) Oct 30
Soleno Therapeutics, Inc. Announces Appointment of Andrew Sinclair in Board of Directors Oct 06
Soleno Therapeutics Announces Updated Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome Oct 01
New 90-day low - €1.53 Jul 27 Shareholder Returns 6XC DE Biotechs DE Market 7D 1.1% 4.0% 0.7% 1Y 25.4% -10.2% 8.4%
See full shareholder returns
Return vs Market: 6XC exceeded the German Market which returned 8.4% over the past year.
Price Volatility Is 6XC's price volatile compared to industry and market? 6XC volatility 6XC Average Weekly Movement 8.4% Biotechs Industry Average Movement 7.3% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.0% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 6XC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6XC's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Founded Employees CEO Website 1999 33 Anish Bhatnagar soleno.life
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017.
Show more Soleno Therapeutics, Inc. Fundamentals Summary How do Soleno Therapeutics's earnings and revenue compare to its market cap? 6XC fundamental statistics Market cap €1.89b Earnings (TTM ) -€127.81m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 6XC income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$131.16m Earnings -US$131.16m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 10:31 End of Day Share Price 2025/01/02 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Soleno Therapeutics, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Brian Skorney Baird Kristen Kluska Cantor Fitzgerald & Co. François Brisebois Craig-Hallum Capital Group LLC
Show 9 more analysts 
